United Therapeutics
UTHR
545.00
+3.38
+0.62%
United Therapeutics
US · UTHR
#836 by market cap
Listed 1970
545.00
+3.38
+0.62%
Live - 5344 symbols - heartbeat 370s ago
· 2026-10-08 06:19
Pre-market
546.17
+0.21%
After-hours
545.00
0.00%
Overnight
546.00
+0.18%
- Market cap
- 23.38B
- P/E (TTM)i
- 19.53
- P/Bi
- 3.65
- EPSi
- 27.86
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on UTHR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 20.93, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +10.61% YoY
Margins
- Gross margin
- 87.92%
- Operating margin
- 47.67%
- Net margin
- 41.94%
Key ratios & quality
- PEG ratioi
- 0.87
- Altman Z-Scorei
- 20.93
PEG uses trailing P/E against the 3-year net income growth rate (22.43%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.63B | 1.45B | 1.48B | 1.69B | 1.94B | 2.33B | 2.88B | 3.18B |
| Gross profit | 1.43B | 1.33B | 1.38B | 1.56B | 1.78B | 2.07B | 2.57B | 2.80B |
| Selling & admin expenses | 265.80M | 336.20M | 423.90M | 467.00M | 482.10M | 477.10M | 638.60M | 731.10M |
| Research & development | 357.90M | 1.18B | 357.70M | 540.10M | 322.90M | 408.00M | 481.00M | 550.00M |
| Operating profit | 805.40M | -187.60M | 593.60M | 555.90M | 979.70M | 1.18B | 1.45B | 1.52B |
| Pretax profit | 758.90M | -165.00M | 638.90M | 593.90M | 950.60M | 1.27B | 1.54B | 1.71B |
| Tax | 169.70M | -60.50M | 124.10M | 118.10M | 223.30M | 289.50M | 343.90M | 379.20M |
| Net profit | 589.20M | -104.50M | 514.80M | 475.80M | 727.30M | 984.80M | 1.20B | 1.33B |
| Basic EPS | 14 | -2 | 12 | 11 | 16 | 21 | 26 | 30 |
| Diluted EPS | 13.39 | -2.39 | 11.54 | 10.06 | 15.00 | 19.81 | 24.64 | 27.86 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 794.40M | 798.60M | 799.50M | 790.20M | 781.50M | 783.30M |
| Gross profit | 701.90M | 711.00M | 698.60M | 686.80M | 648.10M | 683.80M |
| Selling & admin expenses | 170.10M | 190.80M | 181.80M | 189.80M | 184.10M | 206.70M |
| Research & development | 149.00M | 134.00M | 127.50M | 139.50M | 138.20M | 146.30M |
| Operating profit | 382.80M | 386.20M | 389.30M | 357.50M | 325.80M | 330.80M |
| Pretax profit | 423.50M | 408.40M | 438.00M | 444.00M | 318.30M | 372.70M |
| Tax | 101.30M | 98.90M | 99.30M | 79.70M | 43.40M | 39.70M |
| Net profit | 322.20M | 309.50M | 338.70M | 364.30M | 274.90M | 333.00M |
| Basic EPS | 7 | 7 | 8 | 8 | 6 | 8 |
| Diluted EPS | 6.63 | 6.41 | 7.16 | 7.70 | 5.82 | 7.27 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.77B | 1.86B | 2.17B | 2.32B | 3.38B | 3.55B | 3.87B | 3.70B |
| Cash & ST investments | 1.42B | 1.49B | 1.84B | 1.93B | 2.84B | 2.99B | 3.27B | 2.92B |
| Inventory | 101.00M | 93.40M | 86.50M | 93.80M | 102.00M | 111.80M | 157.90M | 183.10M |
| Total assets | 3.40B | 3.91B | 4.62B | 5.17B | 6.04B | 7.17B | 7.36B | 7.88B |
| Total current liabilities | 276.60M | 463.00M | 323.30M | 305.40M | 343.20M | 804.40M | 738.10M | 560.60M |
| Short-term debt | -- | 250.00M | -- | -- | -- | 400.00M | 300.00M | -- |
| Long-term debt | 250.00M | 600.00M | 800.00M | 800.00M | 800.00M | 300.00M | -- | -- |
| Total liabilities | 593,200,000.00 | 1,133,000,000.00 | 1,219,800,000.00 | 1,210,200,000.00 | 1,247,800,000.00 | 1,182,200,000.00 | 920,000,000.00 | 783,800,000.00 |
| Total equity | 2.81B | 2.78B | 3.40B | 3.96B | 4.80B | 5.98B | 6.44B | 7.10B |
| Retained earnings | 3.43B | 3.33B | 3.84B | 4.32B | 5.04B | 6.03B | 7.22B | 8.56B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.94B | 3.83B | 3.49B | 3.70B | 2.87B | 3.48B |
| Cash & ST investments | 3.32B | 3.05B | 2.77B | 2.92B | 2.15B | 2.66B |
| Inventory | 165.40M | 169.20M | 176.50M | 183.10M | 178.30M | 193.80M |
| Total assets | 7.74B | 7.91B | 7.35B | 7.88B | 6.71B | 7.22B |
| Total current liabilities | 721.50M | 527.10M | 546.30M | 560.60M | 599.10M | 607.80M |
| Short-term debt | 200.00M | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 936,700,000.00 | 734,400,000.00 | 760,900,000.00 | 783,800,000.00 | 813,100,000.00 | 819,800,000.00 |
| Total equity | 6.81B | 7.17B | 6.59B | 7.10B | 5.90B | 6.40B |
| Retained earnings | 7.54B | 7.85B | 8.19B | 8.56B | 8.83B | 9.16B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 778.40M | -206.60M | 755.70M | 598.20M | 802.50M | 978.00M | 1.33B | 1.56B |
| Depreciation & amortization | 35.90M | 45.90M | 49.90M | 49.90M | 51.30M | 53.20M | 72.50M | 85.60M |
| Free cash flow | 594.00M | -290.30M | 696.40M | 477.40M | 663.70M | 747.60M | 1.08B | 1.04B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -2.10M | -3.70M | -10.80M | -11.40M | -13.80M | -1.01B | -1.02B |
| Ending cash balance | 669.20M | 738.40M | 738.70M | 894.80M | 961.20M | 1.21B | 1.70B | 1.56B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 461.20M | 191.70M | 562.10M | 346.20M | 463.30M | 313.60M |
| Depreciation & amortization | 19.80M | 21.10M | 21.90M | 22.80M | 22.60M | 24.20M |
| Free cash flow | 386.30M | 129.50M | 346.10M | 173.30M | 362.50M | 205.60M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -20.50M | -1.00B | 4.40M | -1.50B | -58.80M |
| Ending cash balance | 1.90B | 1.59B | 1.34B | 1.56B | 1.28B | 1.80B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 24.10 | -3.75 | 16.67 | 12.94 | 16.61 | 18.27 | 19.23 | 19.71 |
| ROA %i | 18.76 | -2.86 | 12.07 | 9.73 | 12.97 | 14.91 | 16.45 | 17.51 |
| ROIC %i | 21.44 | -3.02 | 13.48 | 10.66 | 13.86 | 14.28 | 16.35 | 17.73 |
| 5-year avg ROE %i | 31.99 | 25.80 | 19.93 | 14.22 | 13.31 | 12.15 | 16.74 | 17.35 |
| EBIT margin %i | 47.48 | -8.34 | 44.66 | 36.34 | 50.77 | 57.30 | 54.98 | 54.46 |
| FCF / sales %i | 36.49 | -- | 46.95 | 28.32 | 34.28 | 32.12 | 37.55 | 32.53 |
| Current ratioi | 6.39 | 4.03 | 6.70 | 7.61 | 9.85 | 4.41 | 5.25 | 6.60 |
| Quick ratioi | 5.75 | 3.54 | 6.16 | 6.97 | 8.91 | 4.07 | 4.80 | 5.83 |
| Debt / assetsi | 7.35 | 21.72 | 17.33 | 15.48 | 13.24 | 9.77 | 4.07 | -- |
| LT debt / equityi | 8.97 | 21.58 | 23.56 | 20.21 | 16.68 | 5.01 | -- | -- |
| Interest coveragei | 55.60 | -2.73 | 28.19 | 32.93 | 30.34 | 22.49 | 36.87 | 88.89 |
| Revenue CAGR (3Y) %i | 3.56 | -3.23 | -4.91 | 1.17 | 10.15 | 16.20 | 19.52 | 18.02 |
| Net income CAGR (3Y) %i | -3.30 | -- | 7.20 | -6.88 | -- | 24.14 | 35.93 | 22.43 |
| FCF CAGR (3Y) %i | 21.28 | -- | 21.54 | -7.03 | -- | 2.39 | 31.30 | 15.97 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 19.94 | 19.30 | 20.04 | 19.71 | 20.26 | 19.32 |
| ROA %i | 17.01 | 16.98 | 17.57 | 17.51 | 17.81 | 17.33 |
| ROIC %i | 17.05 | 17.27 | 17.95 | 17.73 | 18.17 | 17.46 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 53.43 | 53.56 | 54.04 | 54.46 | 51.27 | 50.25 |
| FCF / sales %i | 37.69 | 34.80 | 35.69 | 32.53 | 31.91 | 34.47 |
| Current ratioi | 5.46 | 7.26 | 6.40 | 6.60 | 4.79 | 5.73 |
| Quick ratioi | 5.05 | 6.50 | 5.61 | 5.83 | 4.12 | 4.89 |
| Debt / assetsi | 2.58 | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 44.81 | 52.50 | 69.58 | 88.89 | 99.09 | 132.08 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Tyvaso DPI is the largest reported line at 41.70% of revenue, across 7 reported segments.
- No single line clears half of revenue; Remodulin is next at 16.12%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Tyvaso DPI41.70%
Remodulin16.12%
Nebulized Tyvaso16.09%
Orenitram16.05%
Unituxin8.32%
Other0.87%
Adcirca0.86%
Quote time 2026-10-08 06:19:20 · For reference only, not investment advice and not tailored to your situation.